- Fisher & Paykel Healthcare’s net income for the first half of the year was NZ$153.2 million, which fell short of the estimated NZ$156.5 million.
- The interim dividend per share was 18.5 NZ cents, lower than the anticipated 19.6 NZ cents.
- Operating revenue surpassed expectations at NZ$951.2 million, compared to the estimated NZ$936 million.
- Analyst recommendations include 1 buy, 9 holds, and 5 sells.
A look at Fisher & Paykel Healthcare Corp Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 2 | |
Growth | 3 | |
Resilience | 4 | |
Momentum | 5 | |
OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Fisher & Paykel Healthcare Corp is positioned for a positive long-term outlook. With a strong momentum score of 5, the company is showing significant potential for growth in the future. This suggests that Fisher & Paykel Healthcare Corp is likely to continue its upward trajectory and outperform market expectations.
Furthermore, the company’s resilience score of 4 indicates a robust ability to weather challenges and adapt to changing market conditions. Along with a growth score of 3, which highlights opportunities for expansion, Fisher & Paykel Healthcare Corp is well-positioned for sustainable development. Although the value and dividend scores are more moderate at 2, the overall outlook for the company appears promising due to its high momentum and resilience factors.
#### Summary: Fisher & Paykel Healthcare Corporation Limited specializes in designing, manufacturing, and marketing heated humidification products and systems for respiratory care and sleep apnea treatment. Additionally, the company offers patient warming and neonatal care products, including warming products and infant resuscitators. ####
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars